IMMU Immunicum AB

Immunicum AB (publ) Announces Appointment of Peter Hein as Interim Chief Financial Officer

Immunicum AB (publ) Announces Appointment of Peter Hein as Interim Chief Financial Officer

Press Release

13 May 2020

Immunicum AB (publ) Announces Appointment of Peter Hein as Interim Chief Financial Officer

Immunicum AB (publ; IMMU.ST) announced today that Peter Hein has been appointed interim Chief Financial Officer (CFO), effective May 18, 2020. The recruitment process for a permanent CFO is ongoing. As previously announced, Michaela Gertz will leave the position as CFO at Immunicum during the second quarter.

“I am pleased that Peter, with his broad background from the life sciences industry combined with a deep financial knowledge has agreed to join Immunicum at this time. This facilitates a seamless transition with the support of Michaela and sufficient time to continue our search for a permanent position,” said Alex Karlsson-Parra, acting CEO of Immunicum.

Peter Hein joins Immunicum with extensive experience from leading positions in the life science industry. He served as CFO at Q-Med, Biolipox (Orexo) and Vice President and CFO at BioArctic AB. He has also held the position of CFO and CEO at Granngården. Mr. Hein also brings experience in business and finance from companies including Eriksson and Swedish Match.

For more information, please contact:

Alex Karlsson-Parra, CSO and Interim CEO, Immunicum

Telephone:

E-mail:   

Michaela Gertz, CFO, Immunicum

Telephone:

E-mail:   

INVESTOR RELATIONS

Jonas Rodny and Carolin Wiken

Paues Åberg Communications

Telephone:

E-mail:  

About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The company’s lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Immunicum has evaluated ilixadencel in several clinical trials including the recently completed exploratory Phase II MERECA study in kidney cancer and the Company is moving towards late-stage clinical development. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm.

 

Attachment

EN
13/05/2020

Underlying

IMMUImmunicum AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immunicum AB

Free Trial
IMMU IMMUNICUM AB

Mendus AB: 2 directors

A director at Mendus AB bought 17,842 shares at 7.566SEK and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

07/22/25 July 22, 2025 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - Collaboration unveils path forward for ilixadencel

Mendus has announced a collaboration with Institut Bergonié, an established comprehensive cancer centre in France, to test ilixadencel in soft tissue sarcomas (STS) as part of an ongoing Phase I/II basket trial (REGOMUNE). The trial is a multi-centre, prospective open-label study assessing the combination of regorafenib (a tyrosine kinase inhibitor) and avelumab (an immune checkpoint inhibitor) in various solid tumours. Ilixadencel will be evaluated along with a combination in one of the treatme...

07/24/24 July 24, 2024 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - Recent clinical data highlight vididencel’s potential

Mendus recently presented positive data from two ongoing clinical studies, ADVANCE II and ALISON, at the EHA and ESMO conferences, respectively. While the Phase I ALISON trial, evaluating lead asset vididencel in ovarian cancer, met its primary endpoint of generating sufficient vaccine-induced responses (VIR), further analysis of ADVANCE II data (studying vididencel as a maintenance therapy in AML) confirmed the drug’s potential in generating a broader immune response through both T-cell and B-c...

06/21/24 June 21, 2024 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - All hands on deck as inflection points approach

With Mendus’s Q124 results, management recapped its clinical priorities, which are all progressing as expected. The focus remains on the AMLM22-CADENCE trial for lead cancer vaccine vididencel, in combination with oral azacitidine as a maintenance treatment for acute myeloid leukaemia (AML). R&D expenses came in slightly ahead of expectations with the ramp up in clinical activity, including preparation for the subsequent pivotal Phase III trial, with large-scale manufacturing of vididencel (plan...

05/20/24 May 20, 2024 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - Gross proceeds of c SEK69m to advance pipeline

Mendus has reported gross proceeds of c SEK69.1m from the exercise of series TO3 warrants that were issued in connection with the July 2023 raise of SEK317m. Management anticipates that these proceeds will extend the cash runway to Q325 and will be applied to progress its clinical pipeline, mainly in preparation for a registrational trial for lead cancer vaccine vididencel, targeting acute myeloid leukaemia (AML) in the maintenance setting. Management expects the registrational study to commence...

04/04/24 April 4, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch